Condition: Hospital Acquired Bacterial Pneumonia (HABP) · Ventilator Associated Bacterial Pneumonia (VABP) · Colistin Resistanrt ABC · Sponsor: BioVersys SAS
This is a two-part study, with Part A being the randomized, controlled portion of the study in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) suspected or confirmed to be due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). Part B is the single-group portion of the study and includes patients with HABP or VABP with CRABC infections that are resistant to or have failed colistin/polymyxin B treatment.
This description comes directly from the study's public registry record.
Glenn Dale · +41 61 633 22 50 · info@bioversys.com
Always discuss trial participation with your own doctor first.
| University Hospital | Tbilisi, Georgia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07326540